Zorginstituut Nederland

What Zorginstituut Nederland does

Zorginstituut Nederland is a Dutch self-governing administrative body (Zelfstandig Bestuursorgaan, ZBO) operating under the Ministry of Health, Welfare and Sport (VWS). Founded in 1949 as the Ziekenfondsraad, it was renamed College voor zorgverzekeringen (CVZ) in 1999 and took its current name in April 2014 when it received expanded statutory tasks covering healthcare quality and professional innovation. The institute advises the Minister of VWS on the contents of the basic health insurance package under the Health Insurance Act (Zvw) and the Long-term Care Act (Wlz), which together cover approximately 17.8 million Dutch residents. It also administers the Zorgverzekeringsfonds and Fonds langdurige zorg, managing financial flows across the Dutch healthcare system where total basic-package costs are projected at €65.6 billion in 2026. Approximately 480-500 employees operate from the Diemen headquarters.

The institute operates a portfolio of independent information portals and databases serving healthcare providers, insurers, patients, and policy-makers. Core products include the Farmacotherapeutisch Kompas (FK), an authoritative medication reference used by physicians, nurses, and pharmacists; Horizonscan Geneesmiddelen, providing pharmaceutical market intelligence; Zorgcijfersdatabank, containing five years of healthcare cost data; iStandaarden (five information exchange standards: iWlz, iWmo, iJw, iPgb, iEB); KIK-V for nursing-home care data exchange; Medicijnkosten for drug reimbursement information; and Zorginzicht for quality standards. The portfolio relies on pseudonymization for privacy-preserving analytics and SAS for data analysis, and the FK is also available as an offline mobile application. The institute does not operate a unified modular platform; each portal is a standalone property.

As a government body, Zorginstituut Nederland is funded through the Dutch state budget and does not sell products or services commercially. Its primary stakeholder is the Dutch Ministry of VWS, with secondary beneficiaries including healthcare providers, health insurers, and Dutch citizens. Distribution occurs through official websites, the quarterly Zorginstituut Magazine, news releases, annual reports, and direct advisory engagement. The organization collaborates closely with the Nederlandse Zorgautoriteit (NZa), the Inspectie voor Gezondheidszorg en Jeugd (IGJ), the College ter Beoordeling van Geneesmiddelen (CBG), Centraal Bureau voor de Statistiek (CBS), medical professional associations, and patient and consumer organizations, and participates in the EU Horizon Europe program.

Name

Zorginstituut Nederland

Legal name

Zorginstituut Nederland

Website

https://zorginstituutnederland.nl

Company type

Private

Founded year

1949

Operating status

Operating

Headcount range

251–500 employees

Short description

Dutch self-governing government body (ZBO) that advises the Minister of Health on the basic healthcare package, manages Zvw and Wlz funds, and operates information portals serving providers, insurers, and 17.8 million Dutch residents.

Ownership category

akta.pro rank

Product category

Healthcare Policy and Insurance Administration

NAICS

Direct Life, Health, and Medical Insurance Carriers (52411), Health and Welfare Funds (525120)

SIC

Hospital & Medical Service Plans (6324), Services-Management Consulting Services (8742)

akta.pro primary industry

Real-World Evidence (RWE) & HEOR for Development (HLAIALAI)

akta.pro secondary industries

Market Access, Pricing & Reimbursement (Evidence Generation) FSP (HLAGAOAN), Real-World Data (RWD) / Real-World Evidence (RWE) & Observational Research Platforms (HLACAOAM), Healthcare Terminology, Ontology & Code Set Management (SNOMED/LOINC/ICD/RxNorm) (HLACAIAF)

Keywords

• Healthcare policy advisory
• Health insurance management
• Pharmaceutical information systems
• Healthcare data analytics
• Government health institute

Headquarters

HQ city

Diemen

HQ country

Netherlands

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Others

Revenue model

1. Government Funding: As a zelfstandig bestuursorgaan (ZBO), the organization is funded through the Dutch Ministry of Health, Welfare and Sport (VWS) budget
2. Healthcare Fund Management: Manages the Zorgverzekeringsfonds (Zvf) and Fonds langdurige zorg (Flz), managing money flows under the Health Insurance Act (Zvw) and Long-term Care Act (Wlz)

Go-to-market motion1 record

Distribution channels3 records

Marketing channels4 records

Core offering

Zorginstituut Nederland is a Dutch self-governing government body (ZBO) that advises the Minister of Health, Welfare and Sport (VWS) on the contents of the basic health insurance package, manages the Zorgverzekeringsfonds (Zvw) and Fonds langdurige zorg (Wlz), and develops information standards for healthcare data exchange. It operates a portfolio of national information portals and databases — including the Farmacotherapeutisch Kompas, Horizonscan Geneesmiddelen, Zorgcijfersdatabank, iStandaarden, KIK-V, Medicijnkosten, and Zorginzicht — providing decision-support information to physicians, insurers, government bodies, and citizens.

Product overview

Zorginstituut Nederland operates as a government health institute managing a portfolio of web-based information portals and databases focused on healthcare quality, pharmaceutical information, and cost data. The core portfolio includes: Farmacotherapeutisch Kompas (FK) as the authoritative drug reference database for Dutch healthcare professionals; Horizonscan Geneesmiddelen providing pharmaceutical market intelligence; iStandaarden (5 information exchange standards) enabling standardized data exchange; KIK-V for nursing home care data improvement; Medicijnkosten for drug pricing and reimbursement information; Zorgcijfersdatabank for healthcare cost analytics; and Zorginzicht for quality standards information. The organization also offers the FK mobile app. These products function as standalone web portals and databases providing healthcare stakeholders with decision-support information. The organization does not operate a unified platform with modular architecture; instead, each product serves as an independent portal.

Differentiator

Problem solved

Functional benefit

Products and services

• Farmacotherapeutisch Kompas (FK) The essential tool for physicians when prescribing medications to patients. Contains expert, independent, and current information about all medicines available in the Netherlands. Used primarily by physicians, nurses, and pharmacists, and also accessible to patients seeking more information.
• Horizonscan Geneesmiddelen Provides a comprehensive, publicly accessible, objective overview of medicines expected to enter the market. Contains information for treatment providers, hospitals, health insurers, government bodies, and patients.
• Informatiestandaarden (iStandaarden) Portal providing 5 information standards for healthcare and support: iWlz, iWmo, iJw, iPgb and iEB. Each standard is a collection of rules and agreements ensuring that client data is exchanged in a standardized, high-quality, and secure manner.
• Keteninformatie Kerngegevens Verbeteren (KIK-V) A national program in which chain parties collaborate involved in data exchange about nursing home care. KIK-V aims to ensure that this exchange works better.
• Medicijnkosten Website where patients and healthcare providers can search for information about the level of reimbursement and reimbursement status of medicines in the Netherlands under the Health Insurance Act (Zvw). Data is updated at the beginning of each month.
• Zorgcijfersdatabank Contains information about the development of healthcare costs in the Netherlands over the past 5 years. The analyses on this website offer starting points for developing and evaluating policy.
• Zorginzicht Provides an overview of national agreements about good care as described in quality standards, measurement instruments, and information standards. Available for everyone involved in improving healthcare quality.
• FK-app (Farmacotherapeutisch Kompas Mobile App) Mobile application for the Farmacotherapeutisch Kompas. Works completely offline, does not collect, store, or share any form of personal user data, account information, or device data. No data is stored on external servers.

Quantifiable outcome

• 6.1% increase in basic package costs to €65.6 billion in 2026
• +1 more outcomes

Named customers4 records

Segments4 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

Nine partnerships are on record, tiered core and minor.

• Nederlandse Zorgautoriteit (NZa)coreStrategic or Co-development PartnerClose collaboration with NZa (Dutch Healthcare Authority) on appropriate care framework development and healthcare system improvements. Jointly published the 'Passende zorg' framework advising on value-driven healthcare organization.
• Inspectie voor Gezondheidszorg en Jeugd (IGJ)coreStrategic or Co-development PartnerCollaboration with IGJ (Health and Youth Care Inspectorate) on healthcare quality and safety matters
• Horizon EuropeminorStrategic or Co-development PartnerParticipates in Horizon Europe, the EU research and innovation program, contributing to gender equality objectives in the European Commission
• Ministerie van Volksgezondheid, Welzijn en Sport (VWS)coreStrategic or Co-development PartnerOperates under the responsibility of the Ministry of VWS as a zelfstandig bestuursorgaan (ZBO). Receives policy mandates and provides advisory services on healthcare insurance and long-term care
• Healthcare Professional AssociationscoreStrategic or Co-development PartnerCollaborates with medical professional associations, patient organizations, and consumer organizations on appropriate care standards and healthcare quality
• Centraal Bureau voor de Statistiek (CBS)minorStrategic or Co-development PartnerWorks with Statistics Netherlands for healthcare data analysis and national statistics
• College ter Beoordeling van Geneesmiddelen (CBG)minorStrategic or Co-development PartnerCollaborates with Medicines Evaluation Board on pharmaceutical assessment matters
• Farmacotherapeutisch Kompas StakeholderscoreStrategic or Co-development PartnerPlatform used primarily by physicians, nurses, and pharmacists for prescribing information. Includes patient access for medication information
• iStandaarden PartnerscoreStrategic or Co-development PartnerPortal for 5 information standards (iWlz, iWmo, iJw, iPgb, iEB) used by implementing organizations, care organizations, VNG, ZN, and NZa

Scale indicators3 records

Recent moves9 records

Expansion highlights5 records

Regional players

• Pharmaceutical Benefits Advisory Committee (PBAC): PBAC is an independent expert body that recommends which medicines should be subsidized under Australia's Pharmaceutical Benefits Scheme. Its cost-effectiveness evaluation methodology and reimbursement recommendation role are directly analogous to Zorginstituut's GVS assessment function.
• CADTH (Canadian Agency for Drugs and Technologies in Health): CADTH provides HTA evidence and reimbursement recommendations to Canadian federal, provincial, and territorial health programs. Its drug reimbursement reviews and health technology assessments parallel Zorginstituut's evidence generation for the Dutch basic package, though serving a different geography.
• Belgian Health Care Knowledge Centre (KCE): KCE is Belgium's federal HTA research center producing analyses to support healthcare policy decisions. Comparable to Zorginstituut in producing evidence-based analyses for reimbursement and health system improvement, but operating in Belgium's distinct federal healthcare structure.
• Norwegian Medicines Agency (Statens Legemiddelverk): The Norwegian Medicines Agency handles marketing authorization, pricing, and reimbursement decisions for medicines in Norway. Comparable in its drug assessment and reimbursement decision role to Zorginstituut's GVS-related functions, operating in a similar Nordic/European single-payer-adjacent system.
• ICER (Institute for Clinical and Economic Review): ICER is a US nonprofit organization that performs independent HTA and value-based price benchmarks for drugs and other interventions. While not government-affiliated like Zorginstituut, it performs comparable clinical and economic evidence reviews that inform US payer reimbursement decisions.

Direct peers

• Haute Autorité de Santé (HAS): HAS is the French independent public authority that assesses medical, economic, and public health dimensions of healthcare interventions for reimbursement decisions. Like Zorginstituut, it provides HTA guidance and publishes clinical guidelines for the French healthcare system.
• Institute for Quality and Efficiency in Health Care (IQWiG): IQWiG is Germany's independent HTA institute that evaluates the benefit of medical interventions for reimbursement decisions in the German statutory health insurance system. It is directly comparable to Zorginstituut's role in assessing medicines for the Dutch basic package under the GVS system.
• National Institute for Health and Care Excellence (NICE): NICE is the UK equivalent of Zorginstituut Nederland, performing health technology assessment and providing evidence-based guidance on which treatments the NHS should fund. Both bodies serve as statutory HTA agencies advising government on reimbursement and appropriate care, with similar methodologies and stakeholder engagement models.
• AIFA (Italian Medicines Agency): AIFA is the Italian regulatory authority that governs pharmaceutical policy, including pricing and reimbursement for medicines reimbursed by the Italian NHS. Its pricing and reimbursement committee (CPR) performs a function analogous to Zorginstituut's GVS assessment role.
• Dental and Pharmaceutical Benefits Agency (TLV): TLV is Sweden's central government agency that determines whether a pharmaceutical or dental product will be subsidized, sets pharmacy retail margins, and monitors the pharmaceutical market. It mirrors Zorginstituut's drug reimbursement and market intelligence functions (Horizonscan-equivalent).

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/cvz
• Xx.com/ZiNLActueel
• Facebookfacebook.com/profile.php

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Subsidiaries8 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Zorginstituut Nederland